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Introduction: TNF-α inhibitors plus MTX appear to have benefit in the longer-term reduction of RA. Boolean
long-term remission under drug-free conditions is rare. The therapeutic mechanism and the factor of predicting
response have not been clarified yet.
Case description: A 24-year-old female rheumatoid arthritis (RA) patient, who once attained complete remission
(CR) with the combination therapy with tumor necrosis factor alpha (TNF-alpha) inhibitor adalimumab (ADA) and
methotrexate (MTX), showed the occurrence of Epstain- Barr virus (EBV)-associated lymphoproliferative disorder
(LPD). Pulse treatment with methylprednisolone after the termination of anti TNF-α therapy resulted in the
remission of EBV-associated LPD. The administration of prednisolone (PSL) was tapered off after the improvement
of clinical symptoms and laboratory data. The patients achieved drug-free 12 months after urgent hospitalization
and delivered healthy baby 2 years after hospital discharge. She has been complete drug-free Boolean remission for
5 years.
Discussion and evaluation: The purpose of this brief case is report that we experienced the remission of LPD after
CR with combined therapy with ADA and MTX. We believe this case report will be one of the paths for unveiling
the pathogenesis and improving the treatment for RA.
Conclusions: We believe this case report will be one of the paths for unveiling the pathogenesis and improving
the treatment for RA.
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Tumor necrosis factor-alpha (TNF-α) inhibitors have
revolutionized the management of RA and other chronic
inflammatory diseases. TNF-α inhibitors plus MTX ap-
pears to have benefit in the longer-term reduction of RA
signs/symptoms in MTX-resistant patients, with no un-
expected safety concerns. Nonetheless, Boolean defined
disease remission occurred in 5.0-10.1% of RA, and
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in any medium, provided the original work is p(Shahouri et al. 2011). Moreover, these drugs have the
increased risk of opportunistic infections and lympho-
proliferative disorder (LPD) (Wolfe and Michaud 2004).
The therapeutic mechanism and the factor of predicting
response have not been clarified yet. Here we reported
an RA patient who developed EBV-associated LPD in
immediately after achieving complete remission (CR) by
combination of low doses of MTX and TNF-α inhibitor
adalimumab (ADA).Case description
A 24-year-old Japanese woman with one year history
of active rheumatoid arthritis (RA) who complained inis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Oda and Minata SpringerPlus  (2015) 4:41 Page 2 of 5March 2007 with pain and swelling of bilateral wrists,
elevation of the inflammatory markers such as C-
reactive protein (CRP), erythrocyte sedimentation rate
(ESR) and matrix metalloproteinase-3 (MMP3). The
blood examination showed anti-agalactosyl IgG antibody
CARF positive, which is known as the early diagnosis
marker for RA (Das et al. 2004). X-ray imaging showed
particular bone erosions in the carpal bones of the hands
and partially ankylosis of the carpal bones (Figure 1). RA
diagnosis was met with the 1987 Rheumatoid Arthritis
Classification. The combination of MTX (6–8 mg/week)
and PSL (3 mg/day) was selected as an initial therapy for
RA in September 2007. After that, however, disease ac-
tivity was increased up to DAS28-CRP 5.1 (over right
fingers, bilateral knees, right index middle ring PIP, and
right ankle) and x-ray showed rapid destructive joints
and high disease activity progression to Steinbrocker
stage classification 3 within half a year after RA diag-
nosis. Then, she was referred to Takatsuki Red Cross
Hospital for administration of anti-TNF-α inhibitor.
Screening test was examined by included laboratory data
with ECG, chest x-ray for excluding tuberculosis (Tbe),
hepatitis C viruses (HCV) and hepatitis B viruses (HBV).
Immunological examinations were tested for rheumatoid
factor (RF) 22 U/ml, MMP-3 654 ng/ml, CRP 7.65 mg/dl,
and ESR 35 mm/h. In August 2008, ADA (40 mg every
other week) was administrated with MTX (8 mg/week).
Seven days after receiving first administration of ADA, she
showed rapid progression of sore throat, high fever and
general lymph nodes swelling. Laboratory tests showed an
elevated white blood cell count (WBC) 31800 (20.6% neu-
trophils and 63.7% lymphocytes without atypical lym-
phocytes), high level of CRP (3.3 mg/dl) and elevated
liver-function tests with alanine aminotransferase level (53
U/L), aspartate aminotransferase (65 U/L), and gamma-
glutamyltransferase (138 U/L). Evaluation of diagnosis
with computed tomography (CT) and ultrasonography
showed cervical and mediastinal lymph node swelling,
multiple nodules measuring up to 13 mm in diameter inFigure 1 X-ray of bilateral fingers and wrists at the diagnosis: A) erosio
demonstrating bone erosion (black arrow) and joint narrowing partiallythe lungs and mild hepatosplenomegary (Figure 2). An in-
guinal lymph node biopsy staining with hematoxylin and
eosin staining (H&E staining) showed proliferation
of the lymphatic cells without tumor cell phenotype
(Figure 3A) and immunohistological studies with this
examined inguinal lymph node revealed the lympho-
proliferative CD20 positive cells (Figure 3B). H&E staining
in high power filed showed the full range of mature
lymphatic cells with polymorphous pattern and phagocytic
macrophages included condensed small nuclear cells sug-
gested apoptotic cell (Figure 3C). Besides, many lymphatic
cells in the inguinal lymph node were positive with cleaved
caspase 3 staining (Figure 3D). Moreover, EBV RNA in
situ hybridization with the biopsy specimen revealed posi-
tive signals in the nucleus of large cells, and EBV DNA
was detected by southern blot analysis (data not shown).
Flow-cytometric analysis of infiltrating lymphocytes in
lymph node showed an abundant population of CD38
positive B cell. In addition to routine blood test and urine
cultures, the histories of infection were collected (e.g.,
HCV, HBV, tuberculosis, cytomegalovirus, parvovirus,
varicella-zoster virus, HIV, EBV). The examinations for all
these infections agents were negative except for high titers
of anti-EBV antigen IgG (Table 1). Taken together these
examinations, we diagnosed EB virus related B-cell LPD
after the treatment with TNF-α inhibitor plus MTX, and
that was in accordance with the 2008 WHO classification.
Combination therapy with ADA plus MTX was termi-
nated and pulse treatment with methylprednisolone was
started. Steroid treatment for 7 days resulted in dramatic
regression of LPD. Moreover, 10 days treatment with
methylprednisolone reached to the complete remission of
arthritis with below detection limits in ESR (3 ~ 11 mm/h),
CRP (<0.3 mg/dl), and low level of MMP-3 (17.3 ~ 59.7
ng/ml) (Figure 4A and B). After the improvement of clin-
ical symptoms and laboratory data, the administration of
PSL was tapered off. She achieved drug-free with the re-
duction of EBV VCA-IgG titers (160 U/ml) 12 months
after the emergent admission, and delivered healthy baby 2ns with deformity of the carpal bones in the hands, B) Left wrist
ankylosis and subluxation of the carpal bones (white arrow).
Figure 2 Computed tomography (CT) from cervical to abdomen: A) and B) cervical lymph nodes swelling (arrows), C) hepatosplenomegary
(arrow heads).
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free Boolean remission for 5 years.
Discussion and evaluation
We described the RA patient who achieved CR with re-
ceiving combined therapy of ADA together with MTX,
and that was followed by the occurrence and steroid-
dependent disappearance of immunodeficiency-associatedFigure 3 Immunohistochemistry of inguinal lymph node: A) Hematoxyli
shows positive with anti-CD 20 antibody (×400 magnification), C) H&E st
diffuse lymphatic cells and phagocytic macrophages included condensed
cells (×400 magnification), D) Lymphatic cells are frequently positive withLPD due to EBV infection. After that, RA patient has
never experienced a recurrence without any medication
for 5 years and delivered a healthy baby.
A recent study shows that the combination therapy
with MTX and TNF-α inhibitor leads to better outcomes
(Upchurch and Kay 2012). To prevent disease progres-
sion, treat-to-target recommendations for RA include
the evaluation and adjustment of drug therapy at leastn and eosin stain (H&E stain) (×40 magnification), B) Immunostaining
aining in high power field shows proliferations of the full range of
small nuclear cells (arrows) suggested the presence of apoptotic
cleaved caspase 3 (×400 magnification).









EBV-LQ-T 5 × 106
CMV-G/EI 25.9
HBsAg, hepatitis B surface antigen; HCV Ab, hepatitis C virus antibody; HIV Ab,
human immunodeficiency virus antibody; SIR-2R, systemic inflammatory response-2
receptor; VCA-IgG, Epstein-Barr virus viral capsid antigen- Immunoglobulin
G; VCA-IgM, Epstein-Barr virus viral capsid antigen- Immunoglobulin M; EBV-EBNA,
Epstein-Barr virus nuclear antigen; EBV-LQ-T, Epstein-Barr virus LQTHIFAEV; CMV-G/
EI, Cytomegalovirus antibody titer.
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disease activity is achieved (Emery et al. 2009). For the
setting of the treatment goal, the identification of effect-
ive predictors associated with good clinical response has
been investigated from both sides of clinical markers
and biomarkers (van den Broek et al. 2013). Further-
more, from the risk-benefit point of view, discontinuing
anti-TNF therapy after sustained remission has emerged
among good-responders (Tanaka 2013).
Pathogenesis of our patient with EBV infection seems
to be one of the possible candidates for CR in RA treat-
ment. RA is characterized by defects in central B cell
tolerance mechanisms and impaired T-cell responses to
EBV antigens (Samuels et al. 2005, Lunemann et al.
2008). In fact, high titer of anti-EBV antibody was de-
tected in our case, suggesting the involvement of the
continuous EBV infection (Toussirot and Roudier 2008).
Moreover, increased viral replication enhances EBV-
specific immune responses in RA, which is followed by
the increased frequencies of EBV-specific and IFN-γ-Figure 4 Changes in inflammation and disease activity: A) CRP & ESR
inflammation and disease activity were improved after terminating of tproducing CD8+ T cells in peripheral blood with high
level of viral genomes (Lunemann et al. 2008). Tan et al.
have reported that the virus-specific CD8+ T cells within
the joint showed activated and differentiated phenotype
and played a ‘bystander’ role in the maintenance of
inflammation in RA patients (Tan et al. 2000). These
immune dysfunctions might be related with the mechan-
ism of RA pathogenesis and the increased risk of lym-
phomas under immunosuppressive therapy. Moreover,
previous study showed that lymphomas are often observed
in EBV-positive patients with RA (Samuels et al. 2005). In
our case, the serum examination before administrating of
TNF-α inhibitors showed high titers of anti-EBV antigen
IgG, and lymph node biopsy after administrating of TNF-
α inhibitors revealed EBV derived LPD. This case report
might suggest a possible predictor for good response and
CR with anti-TNF therapy.
Subsequent mechanistic studies have addressed the
involvement of TNF-α antagonists in TNF induced apop-
tosis. Latest data suggest that reverse signaling can be in-
duced by TNF-α antagonists to induce the cytokine
suppression and apoptosis via ligation of cell surface trans-
membrane TNF (tmTNF) (Wong et al. 2008). Actually
ADA has high potential to induce apoptosis by the bind-
ing to tmTNF-α with its high affinity (Shen et al. 2006),
and Infliximab affects EBV-positive B cell survival due to
the increased expression of TNF-α (Baran-Marszak et al.
2006) suggests that the administration of TNF-α inhibitors
might induce apoptosis in EBV infected B cells due to the
high production of TNF-α in latent infected lymph node.
In our case, we consider the possibility that the anti-TNF
inhibitor induces apoptosis in LPD that leads to complete
remission. The occurrence of LPD in RA patient with re-
ceiving immunosuppressive therapy is recognized as the
“Immunodeficiency-associated LPDs” by the World
Health Organization (WHO) and a possible link between
TNF-α inhibitors treatment and increased risk of lymph-
oma has been suggested (Das et al. 2004). Taken together, B) MMP-3, Clinical course and the treatment showed that the
he MTX and ADA and administrating the steroid pulse treatment.
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caused the driving re-activation of the EBV, and leads to
EBV-associated LPD under immune-suppressive status.
Increased awareness is necessary to monitor the possible
occurrence of LPD before and after starting immune
suppressive therapy.
Conclusions
In this case, we experienced the remission of LPD after
CR with combined therapy with ADA and MTX. RA is a
polygenetic disease, it makes difficult to unveil the patho-
genesis of RA and treatment. More evidence and further
investigations are required for elucidating the mechanism
of complete remission and establishing optimal treatment
strategies.
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